Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 8282391, 16 pages
https://doi.org/10.1155/2017/8282391
Review Article

Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Department of Gastroenterology, Shenyang General Hospital of PLA, No. 83 Wenhua Road Shenyang City, Liaoning 110016, China

Correspondence should be addressed to Guo Xiao-Zhong; moc.nuyila@2691gnohzoaixoug

Received 28 September 2016; Accepted 15 December 2016; Published 7 February 2017

Academic Editor: Sara Trabanelli

Copyright © 2017 Jiang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Bond-Smith, N. Banga, T. M. Hammond, and C. J. Imber, “Pancreatic adenocarcinoma,” British Medical Journal, vol. 344, no. 7857, Article ID e2476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Manuel, “Pancreatic cancer,” New England Journal of Medicine, vol. 362, no. 17, pp. 1605–1617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Arslan and S. Yalcin, “Current and future systemic treatment options in metastatic pancreatic cancer,” Journal of Gastrointestinal Oncology, vol. 5, no. 4, pp. 280–295, 2014. View at Google Scholar
  5. P. K. Darcy, P. Neeson, C. S. Yong, and M. H. Kershaw, “Manipulating immune cells for adoptive immunotherapy of cancer,” Current Opinion in Immunology, vol. 27, no. 1, pp. 46–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. D. Goodman and M. W. A. Saif, “Adjuvant therapy for pancreatic cancer,” Journal of the Pancreas, vol. 15, no. 2, pp. 87–90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. V. J. Picozzi, R. A. Abrams, P. A. Decker et al., “Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG trial Z05031,” Annals of Oncology, vol. 22, no. 2, pp. 348–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Asahara, K. Takeda, K. Yamao, H. Maguchi, and H. Yamaue, “Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer,” Journal of Translational Medicine, vol. 11, no. 1, article no. 291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Bernhardt, M. K. Gjertsen, S. Trachsel et al., “Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study,” British Journal of Cancer, vol. 95, no. 11, pp. 1474–1482, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. T. Brett, S. C. Smith, C. V. Bouvier et al., “Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 20, no. 20, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Cai, Y. Ai, C. Zhang et al., “Clinical efficiency of dendritic cells and cytokine-induced killer cells on local advanced and advanced pancreatic cancer patients,” Chinese Journal of Cancer Biotherapy, vol. 20, no. 4, pp. 449–455, 2013. View at Google Scholar
  12. S. P. Chawla, V. S. Chua, L. Fernandez et al., “Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer,” Molecular Therapy, vol. 18, no. 2, pp. 435–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Endo, T. Saito, A. Kenjo et al., “Phase i trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 19, no. 4, pp. 465–475, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. K. Gjertsen, T. Buanes, A. R. Rosseland et al., “Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma,” International Journal of Cancer, vol. 92, no. 3, pp. 441–450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Kameshima, T. Tsuruma, G. Kutomi et al., “Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients,” Cancer Science, vol. 104, no. 1, pp. 124–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Koido, S. Homma, M. Okamoto et al., “Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer,” Clinical Cancer Research, vol. 20, no. 16, pp. 4228–4239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kondo, S. Hazama, T. Kawaoka et al., “Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes,” Anticancer Research, vol. 28, no. 1 B, pp. 379–387, 2008. View at Google Scholar · View at Scopus
  18. B. Kubuschok, M. Pfreundschuh, R. Breit et al., “Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial,” Human Gene Therapy, vol. 23, no. 12, pp. 1224–1236, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. D. T. Le, E. Lutz, J. N. Uram et al., “Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer,” Journal of Immunotherapy, vol. 36, no. 7, pp. 382–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. T. Le, A. Wang-Gillam, V. Picozzi et al., “Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer,” Journal of Clinical Oncology, vol. 33, no. 12, pp. 1325–1333, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. H. Liu, “Inflence of chemotherapy combined with DC-CIK cell on the immune function in patients with pancreatic cancer,” Chinese Journal for Clinicians, vol. 6, no. 20, pp. 6301–6305, 2012. View at Google Scholar
  22. M. F. Liu, Y. L. Gu, and N. K. Zhai, “Effects of dendritic cells on the immune function of the patients with pancreatic cancer,” Nanjing yi ke da xue xue bao, vol. 30, no. 11, pp. 1649–1652, 2010. View at Google Scholar
  23. G. Middleton, P. Silcocks, T. Cox et al., “Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial,” The Lancet Oncology, vol. 15, no. 8, pp. 829–840, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Nishida, S. Koido, Y. Takeda et al., “Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer,” Journal of Immunotherapy, vol. 37, no. 2, pp. 105–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. V. J. Picozzi, R. K. Ramanathan, M. A. Lowery et al., “(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: a phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies,” European Journal of Cancer, vol. 51, no. 14, pp. 1857–1864, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Qiu, M. M. Yun, M. B. Xu, Y. Z. Wang, and S. Yun, “Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study,” International Journal of Clinical Oncology, vol. 18, no. 4, pp. 657–665, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Sultana, S. Shore, M. G. T. Raraty et al., “Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma,” BMC Cancer, vol. 9, article 66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Suzuki, S. Hazama, T. Ueno et al., “A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer,” Journal of Immunotherapy, vol. 37, no. 1, pp. 36–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Q. X. Wen, Y. Zhu, B. Xu, and M. F. Wang, “The study of clinical application of DC-CIK combined with chemotherapy on advanced pancreatic cancer,” Xiandai zhongxiyi jiehe zazhi, vol. 22, no. 36, pp. 4065–4066, 2013. View at Google Scholar
  30. H. Yanagimoto, H. Shiomi, S. Satoi et al., “A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients,” Oncology Reports, vol. 24, no. 3, pp. 795–801, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Yutani, N. Komatsu, M. Yoshitomi et al., “A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients,” Oncology Reports, vol. 30, no. 3, pp. 1094–1100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. L. Zhang, “Study of the inflence on immunologic balance and clinical effect bychemotherapy combined with DC-CIK cell to patients with pancreatic cancer,” Zhongguo xian dai yi xue za zhi, vol. 24, no. 9, pp. 42–45, 2014. View at Google Scholar
  33. I. Melero, G. Gaudernack, W. Gerritsen et al., “Therapeutic vaccines for cancer: an overview of clinical trials,” Nature Reviews Clinical Oncology, vol. 11, no. 9, pp. 509–524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Rahib, B. D. Smith, R. Aizenberg, A. B. Rosenzweig, J. M. Fleshman, and L. M. Matrisian, “Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states,” Cancer Research, vol. 74, no. 11, pp. 2913–2921, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. J. N. Uram and D. T. Le, “Current advances in immunotherapy for pancreatic cancer,” Current Problems in Cancer, vol. 37, no. 5, pp. 273–279, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. D. Plate, “Advances in therapeutic vaccines for pancreatic cancer,” Discovery medicine, vol. 14, no. 75, pp. 89–94, 2012. View at Google Scholar · View at Scopus
  37. J. Yuan, “Circulating protein and antibody biomarker for personalized cancer immunotherapy,” Journal for ImmunoTherapy of Cancer, vol. 4, article 46, 2016. View at Publisher · View at Google Scholar
  38. J. Yokokawa, C. Palena, P. Arlen et al., “Identification of novel human CTL epitopes and their agonist epitopes of mesothelin,” Clinical Cancer Research, vol. 11, no. 17, pp. 6342–6351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. R. Brahmer, “PD-1-targeted immunotherapy: recent clinical findings,” Clinical Advances in Hematology and Oncology, vol. 10, no. 10, pp. 674–675, 2012. View at Google Scholar · View at Scopus
  40. R. E. Royal, C. Levy, K. Turner et al., “Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma,” Journal of Immunotherapy, vol. 33, no. 8, pp. 828–833, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Chen and X. Zhang, “Primary analysis for clinical efficacy of immunotherapy in patients with pancreatic cancer,” Immunotherapy, vol. 8, no. 2, pp. 223–234, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Kubuschok, F. Neumann, R. Breit et al., “Naturally occurring T-cell response against mutated p21 Ras oncoprotein in pancreatic cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1365–1372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Wenandy, R. B. Sørensen, L. Sengeløv, I. M. Svane, P. T. Straten, and M. H. Andersen, “The immunogenicity of the hTERT540-548 peptide in cancer,” Clinical Cancer Research, vol. 14, no. 1, pp. 4–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. Z.-X. Wang, J.-X. Cao, M. Wang et al., “Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis,” Cytotherapy, vol. 16, no. 7, pp. 934–945, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Rahir and M. Moser, “Tumor microenvironment and lymphocyte infiltration,” Cancer Immunology, Immunotherapy, vol. 61, no. 6, pp. 751–759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Chen, X.-Z. Guo, H.-Y. Li, D. Wang, and X.-D. Shao, “Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell,” Experimental Biology and Medicine, vol. 240, no. 10, pp. 1310–1318, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Mariucci, B. Rovati, M. Manzoni et al., “Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors,” Clinical and Experimental Medicine, vol. 11, no. 4, pp. 199–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Jimenez-Luna, J. Prados, R. Ortiz, C. Melguizo, C. Torres, and O. Caba, “Current status of immunotherapy treatments for pancreatic cancer,” Journal of Clinical Gastroenterology, vol. 50, no. 10, pp. 836–848, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Hillyer, N. Raviv, D. M. Gold et al., “Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4+ T cells,” European Journal of Immunology, vol. 43, no. 12, pp. 3197–3208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Ghiringhelli, C. Menard, P. E. Puig et al., “Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,” Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641–648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. D. O'Mahony, J. C. Morris, C. Quinn et al., “A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy,” Clinical Cancer Research, vol. 13, no. 3, pp. 958–964, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. K. J. Lee, S. W. Yi, M. J. Chung et al., “Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma,” Yonsei Medical Journal, vol. 54, no. 3, pp. 643–649, 2013. View at Publisher · View at Google Scholar · View at Scopus